Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

EMBO Molecular Medicine

Volumn 5, Issue 7, 2013, Pages 1051-1066

  Tan, Tuan Zea ^a   Miow, Qing Hao ^a,b   Huang, Ruby Yun Ju ^a,c   Wong, Meng Kang ^a   Ye, Jieru ^a   Lau, Jieying Amelia ^a   Wu, Meng Chu ^a   Bin Abdul Hadi, Luqman Hakim ^a   Soong, Richie ^a   Choolani, Mahesh ^c   Davidson, Ben ^d,e   Nesland, Jahn M ^d,e   Wang, Ling Zhi ^a,f   Matsumura, Noriomi ^g   Mandai, Masaki ^g   Konishi, Ikuo ^g   Goh, Boon Cher ^a,c,f   Chang, Jeffrey T ^h   Thiery, Jean Paul ^a,f,i   Mori, Seiichi ^a,f,j  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g KYOTO UNIVERSITY   (Japan)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^j CANCER INSTITUTE   (Japan)

more..

Author keywords

Cell line model for subtype; Functional genomic screen; Molecular subtype; Ovarian cancer; Tubulin

Indexed keywords

NAVELBINE; SHORT HAIRPIN RNA; VINCRISTINE;

ADULT; API B; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL GROWTH; CELL HETEROGENEITY; CELL LINE; CONTROLLED STUDY; EPI A; ESSENTIAL GENE; FEMALE; FUNCTIONAL GENOMICS; GENE; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MES; MICROTUBULE ASSEMBLY; MOLECULAR TYPING; NZT10 GENE; OVARY CARCINOMA; PRIORITY JOURNAL; STEM A; STEM B; TUBGCP4 GENE;

EID: 84880019576     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201823     Document Type: Article

References (79)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511
2. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, et al (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6: 1678-1690
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43
4. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112
5. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428
6. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357
7. Blum A, Kalai A, Langford J (1999) Beating the hold-out: bounds for K-fold and progressive cross-validation. In Proceedings of the twelfth annual conference on Computational learning theory pp 203-208. Santa Cruz, California, USA: ACM
8. Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, McDonald JF (2009) Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics 2: 71
9. Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145
10. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, et al (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8: R34
11. Chen C, Grennan K, Badner J, Zhang D, Gershon E, Jin L, Liu C (2011) Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods. PloS ONE 6: e17238
12. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, et al (2011) Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108: 12372-12377
13. Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25: 534-555
14. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd edition. Lawrence Erlbaum Associates: New Jersey, USA.
15. Dabney AR (2006) ClaNC: point-and-click software for classifying microarrays to nearest centroids. Bioinformatics 22: 122-123
16. Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D, Zeillinger R, Weichert W, Noske A, Buckendahl AC, et al (2009) A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol 218: 273-280
17. Ewens WJ, Grant GR (2001) Statistical Methods in Bioinformatics. An Introduction. Springer-Verlag Inc., New York
18. Fava F, Raynaud-Messina B, Leung-Tack J, Mazzolini L, Li M, Guillemot JC, Cachot D, Tollon Y, Ferrara P, Wright M (1999) Human 76p: a new member of the gamma-tubulin-associated protein family. J Cell Biol 147: 857-868
19. Fox N, Mathers N (1997) Empowering research: statistical power in general practice research. Family Pract 14: 324-329
20. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al (2010) A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 107: 6994-6999
21. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315
22. George SL (1996) Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14: 1364-1370
23. Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40: 1213-1223
24. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104: 311-325
25. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, et al (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 6: e18064
26. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66: 1354-11362
27. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98: 66-73
28. Howell SJ (2013) Advances in the treatment of luminal breast cancer. Curr Opin Obstet Gynecol 25: 49-54
29. Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, et al (2007) Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25: 4350-4357
30. Huang RY, Wang SM, Hsieh CY, Wu JC (2008) Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin. Int J Cancer 123: 801-809
31. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458
32. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, et al (2010) Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res 70: 2126-2135
33. Jochumsen KM, Tan Q, Holund B, Kruse TA, Mogensen O (2007) Gene expression in epithelial ovarian cancer: a study of intratumor heterogeneity. Int J Gynecol Cancer 17: 979-985
34. Jochumsen KM, Tan Q, Hogdall EV, Hogdall C, Kjaer SK, Blaakaer J, Kruse TA, Mogensen O (2009) Gene expression profiles as prognostic markers in women with ovarian cancer. Int J Gynecol Cancer 19: 1205-1213
35. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127
36. Kim J-H (2009) Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap. Comput Stat Data Anal 53: 3735-3745
37. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, et al (2011) The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 35: 904-912
38. Konavi R (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. In 14th International Joint Conference on Artificial intelligence pp 1137-1143
39. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28: 3555-3561
40. Liu H, Yang R, Tinner B, Choudhry A, Schutze N, Chaqour B (2008a) Cysteine-rich protein 61 and connective tissue growth factor induce deadhesion and anoikis of retinal pericytes. Endocrinology 149: 1666-1677
41. Liu Y, Hayes DN, Nobel A, Marron JS (2008b) Statistical significance of clustering for high-dimension, low-sample size data. J Am Stat Assoc 103: 1281-1293
42. Lobert S, Vulevic B, Correia JJ (1996) Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35: 6806-6814
43. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, et al (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105: 20380-20385
44. Manfredi JJ, Horwitz SB (1984) Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Therapeut 25: 83-125
45. Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, Moriya Y, Hirohashi S (2000) Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 59: 302-309
46. Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, Iversen ES, Berchuck A, Murphy SK (2011) Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res 21: 74-82
47. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
48. Meyniel JP, Cottu PH, Decraene C, Stern MH, Couturier J, Lebigot I, Nicolas A, Weber N, Fourchotte V, Alran S, et al (2010) A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. BMC Cancer 10: 222
49. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, et al (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283-1298
50. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, et al (2009) A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16: 521-532
51. Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L (2012) Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 128: 573-578
52. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, et al (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851-1861
53. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28: 2796-2805
54. Moritz M, Braunfeld MB, Sedat JW, Alberts B, Agard DA (1995) Microtubule nucleation by gamma-tubulin-containing rings in the centrosome. Nature 378: 638-640
55. Moritz M, Zheng Y, Alberts BM, Oegema K (1998) Recruitment of the gamma-tubulin ring complex to Drosophila salt-stripped centrosome scaffolds. J Cell Biol 142: 775-786
56. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527
57. Pejovic T, Pande NT, Mori M, Mhawech-Fauceglia P, Harrington C, Mongoue-Tchokote S, Dim D, Andrews C, Beck A, Tarumi Y, et al (2009) Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Transl Oncol 2: 341-349
58. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
59. Quintas-Cardama A, Kantarjian H, Cortes J (2009) Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6: 535-543
60. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38: 500-501
61. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM (2006) Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 3: 715-719
62. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M (2010) Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 22: 112-120
63. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834
64. Shen Q, Zheng X, McNutt MA, Guang L, Sun Y, Wang J, Gong Y, Hou L, Zhang B (2009) NAT10, a nucleolar protein, localizes to the midbody and regulates cytokinesis and acetylation of microtubules. Exp Cell Res 315: 1653-1667
65. Sims D, Mendes-Pereira AM, Frankum J, Burgess D, Cerone MA, Lombardelli C, Mitsopoulos C, Hakas J, Murugaesu N, Isacke CM, et al (2011) High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol 12: R104
66. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167
67. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
68. Subramanian J, Simon R (2011) An evaluation of resampling methods for assessment of survival risk prediction in high-dimensional settings. Stat Med 30: 642-653
69. Syrjanen K, Syrjanen S (2013) Detection of human papillomavirus in sinonasal papillomas: systematic review and meta-analysis. Laryngoscope 123: 181-192
70. The Cancer Genome Atlas Research Network. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615
71. Therneau TM, Grambsch PM (2000) Modeling Survival Data. Extending the Cox Model. Springer-Verlag Inc., New York
72. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA (2008) Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 14: 4067-4078
73. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208
74. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, et al (2009) PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22: 1243-1250
75. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11: 719-725
76. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110
77. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, et al (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123: 517-525
78. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972-1977
79. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206